Form 4: Xenon Pharmaceuticals Director Dawn Svoronos Acquires Stock Options

Dawn Svoronos, a director at Xenon Pharmaceuticals Inc., acquired stock options for 15,542 common shares on June 5, 2024.

Summary

• On June 5, 2024, Dawn Svoronos, a director of Xenon Pharmaceuticals Inc., acquired stock options.
• The stock options grant the right to buy 15,542 common shares at an exercise price of $38.16.
• The options vest on the earlier of June 4, 2025, or the day before the company's 2025 annual meeting of shareholders.
• The options expire on June 4, 2034.
• Following the transaction, Dawn Svoronos directly owns 15,542 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment. This is a standard disclosure of stock option acquisition by a director. It doesn't inherently indicate positive or negative sentiment, but rather a routine transaction.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance.

Industry Context

This is a routine disclosure related to insider transactions, common in the pharmaceutical industry where stock options are frequently used as part of executive compensation packages.

Comparison to Industry Standards

• Stock option grants are a common component of compensation packages for directors and officers in publicly traded pharmaceutical companies.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their executive compensation plans.
• The vesting schedules and exercise prices are typically structured to align with long-term company performance and shareholder value creation.

Stakeholder Impact

• The acquisition of stock options by a director could have a minor positive impact on shareholder sentiment, as it may signal confidence in the company's future prospects.

Key Dates